Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,418 active trials60 approved drugs271 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,888 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,375)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02911142 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04033302 | Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 |
| clinicaltrials |
| NCT04288726 | Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas | active not recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05995028 | Universal 4SCAR7U Targeting CD7-positive Malignancies | not yet recruiting | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06006741 | Universal CAR-T Cells Targeting Multiple Myeloma | not yet recruiting | Phase 1 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06227026 | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies(PRODIGY) | recruiting | Phase 1 | 10 | University of UtahOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07166419 | Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07691606 | A Study of ARC-02 in B-cell NHL(ABLATE-101) | recruiting | Phase 1 | 140 | Taiho Oncology, Inc.INDUSTRY | 6 | Aug 26, 2026 | clinicaltrials |
| NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 70 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05389423 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | recruiting | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05826535 | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 270 | Lyell Immunopharma, Inc.INDUSTRY | 2 | Aug 25, 2026 | clinicaltrials |
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 38 | Yazeed SawalhaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784309 | A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies | enrolling by invitation | Phase 1 | 13 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT01297764 | A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma(QUAD) | active not recruiting | Phase 1 / Phase 2 | 17 | Hackensack Meridian HealthOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06087653 | Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 24 | Starton Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07220616 | A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 420 | Daiichi SankyoINDUSTRY | 4 | Aug 24, 2026 | clinicaltrials |
| NCT02160015 | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03150329 | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | active not recruiting | Phase 1 | 52 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03884998 | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | recruiting | Phase 1 / Phase 2 | 146 | BeiGeneINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07667868 | A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 18 | BrightPath Biotherapeutics Co., Ltd.INDUSTRY | 0 | Aug 21, 2026 | clinicaltrials |
| NCT02879695 | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | active not recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04007029 | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06495723 | Polyspecific Antibodies in Lymphoproliferative T-cell Disorders(PALT1) | recruiting | Phase 1 / Phase 2 | 54 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT00336063 | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 4 | Aug 19, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 37 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06569147 | Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07070219 | A Study of CTD402 in T-ALL/LBL Patients(TENACITY-01) | recruiting | Phase 1 / Phase 2 | 118 | Imviva BioINDUSTRY | 2 | Aug 19, 2026 | clinicaltrials |
| NCT05651932 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | recruiting | Phase 1 | 165 | K36 Therapeutics, Inc.INDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT07153796 | A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT05169515 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 121 | Hoffmann-La RocheINDUSTRY | 5 | Aug 17, 2026 | clinicaltrials |
| NCT05850234 | AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)(DURGA-1) | recruiting | Phase 1 / Phase 2 | 232 | AstraZenecaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05950165 | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 37 | Cho Pharma Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06042725 | MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | active not recruiting | Phase 1 | 16 | Mayo ClinicOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06927466 | A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. | recruiting | Phase 1 | 33 | Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07105059 | A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07341867 | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | recruiting | Phase 1 | 90 | Andrew Hantel, MDOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | not yet recruiting | Phase 1 / Phase 2 | 274 | Umoja BiopharmaINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT07735546 | A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 100 | Umoja BiopharmaINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT03843294 | Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma | active not recruiting | Phase 1 | 18 | Catherine BollardOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05675449 | A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma(MagnetisMM-20) | active not recruiting | Phase 1 | 59 | PfizerINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT06622005 | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 26, 2026source: clinicaltrials